ArticleAnais brasileiros de dermatologia
Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion.
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesEpiplakin is a member of the plakin family of proteins involved in cytoskeletal organization, yet its role in skin cancers remains poorly understood. This study aimed to evaluate epiplakin expression in cutaneous skin lesions and to investigate its association with epithelial-mesenchymal transition markers and tumor progression.
methodsThe authors retrospectively analyzed skin specimens from squamous cell carcinomas, basal cell carcinomas, and benign intradermal nevi collected between 2021 and 2025. Histopathological features were assessed, and immunohistochemical analysis of Epiplakin, E-cadherin, and N-cadherin was performed. Epiplakin expression was quantified and correlated with cadherin levels and Breslow thickness. Plakin family protein-protein interaction networks were analyzed using KEGG pathway and GO functional enrichment.
resultsProtein-protein interaction network analysis demonstrated that plakin family members are associated with multiple cancer-related pathways, with a prominent enrichment in regulating cell proliferation. Epiplakin expression was significantly higher in squamous cell carcinomas (389.94 ± 70.56) compared with basal cell carcinomas (70.39 ± 15.32) and intradermal nevi, while basal cell carcinomas showed a significant decrease compared with normal skin (p < 0.05). In non-melanoma skin cancers, epiplakin expression demonstrated a strong positive correlation with E-cadherin (r = 0.565, p < 0.001) and a weak positive correlation with N-cadherin (r = 0.329, p < 0.05). No significant correlation was observed with Breslow thickness (p > 0.05). STUDY LIMITATIONS: Retrospective design and the absence of high-grade squamous cell carcinoma cases in the study population.
conclusionsThis is the first study to assess epiplakin expression among epithelial cutaneous cancers. Epiplakin appears to be associated with epithelial-mesenchymal transition and early tumor progression, and its differential expression pattern may provide diagnostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.